Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives.

Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need.

Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

Biotechnology

Education

Walden Biosciences

Blaine Mckee

Andres Rodriguez-Roman

Thomas Miller

Sanja Sever

Ming Proschitsky

Joshua Lapin

Curt Dewan

Alex Duncan

The Leadership Team at Walden Biosciences is responsible for charting the strategic direction of the company, driving innovation in drug discovery, and overseeing the development of targeted therapies for kidney disease. Comprising seasoned experts in biotechnology and medicine, this team fosters a collaborative culture that emphasizes data-driven decision-making, ensuring that the company remains at the forefront of transforming kidney disease treatment. They lead by example, inspiring a dynamic workforce committed to making a meaningful impact on patients’ lives.

Leadership Team

Scientific Team

Leadership Team

About

Team members

Other teams at Walden Biosciences

Scientific Team